Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
PEGS Boston SummitPEGS Boston Summit
Not Confirmed
Not Confirmed
11 May-15 November, 2026
Not Confirmed
Not Confirmed
19-21 June, 2026
BIO International Conv...BIO International Convention
Not Confirmed
Not Confirmed
22-25 June, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
PEGS Boston Summit
Not Confirmed
Contact SupplierPEGS Boston Summit
PEGS Boston SummitPEGS Boston Summit
Industry Trade Show
Not Confirmed
11 May-15 November, 2026
Industry Trade Show
Not Confirmed
19-21 June, 2026
BIO International Conv...BIO International Convention
Industry Trade Show
Not Confirmed
22-25 June, 2026
Digital content
NEWS #PharmaBuzz
13 May 2026
// FDA
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-may-13-2026-53100.pdf
04 May 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/b-braun-launches-rocuronium-bromide-injection-in-a-room-temperature-stable-prefilled-syringe-302761440.html
28 Apr 2026
// FIRSTWORD PHARMA
28 Apr 2026
// FDA
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/b-braun-medical-inc-issues-voluntary-nationwide-recall-lactated-ringers-injection-1l-e7500-due
26 Feb 2026
// PHARMIWEB
https://www.pharmiweb.com/press-release/2026-02-26/b-braun-joins-the-bookdialysiscom-global-holiday-dialysis-network
08 Dec 2025
// INDPHARMAPOST
https://www.indianpharmapost.com/rd/b-braun-unveils-ready-to-use-antibiotic-system-18492
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
Certificate Number : R1-CEP 2014-107 - Rev 00
Issue Date : 2020-04-09
Type : Chemical
Substance Number : 1785
Status : Valid
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 2773
Submission : 1976-10-25
Status : Inactive
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7074
Submission : 1987-06-30
Status : Inactive
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 2665
Submission : 1976-04-30
Status : Inactive
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4223
Submission : 1981-07-21
Status : Inactive
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5188
Submission : 1983-12-22
Status : Inactive
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33965
Submission : 2020-02-21
Status : Inactive
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Drugs in Development
Details:
Rocuronium Bromide, a miscellaneous product targeting the Acetylcholinesterase receptor, shows promise in improving anesthesia outcomes.
Lead Product(s): Rocuronium Bromide
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 04, 2026
Lead Product(s) : Rocuronium Bromide
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
B. Braun Introduces Rocuronium Bromide in Room-Temperature Prefilled Syringe
Details : Rocuronium Bromide, a miscellaneous product targeting the Acetylcholinesterase receptor, shows promise in improving anesthesia outcomes.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 04, 2026
Details:
Gelaspan is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Sepsis.
Lead Product(s): Gelaspan
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Recipient: Shanghai Zhongshan Hospital
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 15, 2025
Lead Product(s) : Gelaspan
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Recipient : Shanghai Zhongshan Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Gelaspan vs Crystalloid Therapy in Sepsis
Details : Gelaspan is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Sepsis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 15, 2025
Details:
Heparin sodium is an anticoagulant, or "blood thinner," used to prevent and treat blood clots by inhibiting thrombin and other clotting factors via the antithrombin III complex.
Lead Product(s): Heparin Sodium
Therapeutic Area: Hematology Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 18, 2025
Lead Product(s) : Heparin Sodium
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
B. Braun Expands Heparin Sodium Injection Portfolio To Seven Products
Details : Heparin sodium is an anticoagulant, or "blood thinner," used to prevent and treat blood clots by inhibiting thrombin and other clotting factors via the antithrombin III complex.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 18, 2025
Details:
Piperacillin, a penicillin-class antibacterial, and Tazobactam, a beta-lactamase inhibitor, in the DUPLEX Drug Delivery System and Sodium Chloride, indicated for Intra-abdominal infections.
Lead Product(s): Piperacillin Sodium,Tazobactam Sodium
Therapeutic Area: Infections and Infectious Diseases Brand Name: Piperacillin and Tazobactam for Injection
Study Phase: Approved FDFProduct Type: Antibiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 09, 2025
Lead Product(s) : Piperacillin Sodium,Tazobactam Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
B. Braun Gains FDA Approval for DUPLEX Delivery of Piperacillin Combo
Details : Piperacillin, a penicillin-class antibacterial, and Tazobactam, a beta-lactamase inhibitor, in the DUPLEX Drug Delivery System and Sodium Chloride, indicated for Intra-abdominal infections.
Product Name : Piperacillin and Tazobactam for Injection
Product Type : Antibiotic
Upfront Cash : Inapplicable
April 09, 2025
Details:
Cefazolin sodium is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. It is indicated for several infections, like respiratory, urinary infections in adult and pediatric.
Lead Product(s): Cefazolin Sodium,Dextrose
Therapeutic Area: Infections and Infectious Diseases Brand Name: Cefazolin Sodium Injection
Study Phase: Approved FDFProduct Type: Antibiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 24, 2025
Lead Product(s) : Cefazolin Sodium,Dextrose
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
B. Braun Launches Ready-to-Activate Cefazolin 3 Gram Pre-Mix in DUPLEX® Containers
Details : Cefazolin sodium is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. It is indicated for several infections, like respiratory, urinary infections in adult and pediatric.
Product Name : Cefazolin Sodium Injection
Product Type : Antibiotic
Upfront Cash : Inapplicable
March 24, 2025
Details:
Levetiracetam is indicated for adjunctive therapy in the treatment of Partial onset seizures in patients one month of age and older with epilepsy.
Lead Product(s): Levetiracetam
Therapeutic Area: Neurology Brand Name: Levetiracetam-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 28, 2024
Lead Product(s) : Levetiracetam
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
B. Braun Launches Levetiracetam in Sodium Chloride Injection Portfolio
Details : Levetiracetam is indicated for adjunctive therapy in the treatment of Partial onset seizures in patients one month of age and older with epilepsy.
Product Name : Levetiracetam-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 28, 2024
Details:
The acquisition includes a qualified cell bank, which is essential for the GMP-compliant manufacturing of Healiva’s first cell therapy product, EpiDex®: an autologous epidermis derived from the patient’s own hair cells.
Lead Product(s): Tissue-engineered Autologous Outer Root Sheath Keratinocyte
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: Epidex
Study Phase: Approved FDFProduct Type: Cell & Gene Therapy
Sponsor: Healiva
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition November 21, 2022
Lead Product(s) : Tissue-engineered Autologous Outer Root Sheath Keratinocyte
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Healiva
Deal Size : Undisclosed
Deal Type : Acquisition
Healiva® Acquires Critical Cell Therapy Manufacturing Assets From B. Braun
Details : The acquisition includes a qualified cell bank, which is essential for the GMP-compliant manufacturing of Healiva’s first cell therapy product, EpiDex®: an autologous epidermis derived from the patient’s own hair cells.
Product Name : Epidex
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
November 21, 2022
Details:
Cefazolin is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Infections.
Lead Product(s): Cefazolin,Dextrose
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 25, 2022
Lead Product(s) : Cefazolin,Dextrose
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics and Safety of Cefazolin 3gm DUPLEX in Adults
Details : Cefazolin is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Infections.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
January 25, 2022
Details:
Chloroprocaine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Lead Product(s): Chloroprocaine
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Recipient: Oregon Health and Science University
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 30, 2019
Lead Product(s) : Chloroprocaine
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Recipient : Oregon Health and Science University
Deal Size : Inapplicable
Deal Type : Inapplicable
Comparison of Clorotekal and Bupivacaine for Short Obstetric Surgery
Details : Chloroprocaine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 30, 2019
Details:
Omega-6 is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Lead Product(s): Omega-6,Omega-3
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 14, 2017
Lead Product(s) : Omega-6,Omega-3
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
The HOME Study (HPN With OMEGA-3)
Details : Omega-6 is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 14, 2017
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients
Inspections and registrations
WHO-GMP
Name and address of WHO GMP certified Manufacturer : M/s. B.Braun Medical (India) Pvt. Ltd., Plot No. 11, 1st Avenue, Mahindra World City, Natham sub post, Chengalpet, Kancheepuram – 602001
Country : U.S.A
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
B. Braun Medical S.A. is a supplier offers 7 products (APIs, Excipients or Intermediates).
Find Hydroxyethyl Starch bulk with CEP offered by B. Braun Medical S.A.
Find Amino Acids, Branched-Chain bulk offered by B. Braun Medical S.A.
Find Cornstarch bulk offered by B. Braun Medical S.A.
Find MOIST HEAT STERILIZATION PARAMETRIC RELEASE PROGRAM (CA AND GA PLANTS) bulk offered by B. Braun Medical S.A.
Find PERSONNEL bulk offered by B. Braun Medical S.A.
Find FACILITIES & GENERAL OPERATING PROCEDS AT IRVINE, CALIF bulk offered by B. Braun Medical S.A.
Find OMEGAFLEX SPECIAL (THREE CHAMBER BAG FOR INFUSION CONTAINING: AMINO ACIDS, GLUCOSE, AND LIPID EMULSION) bulk offered by B. Braun Medical S.A.
Share 
